Biovista began work today on one clinical candidate and one pre-clinical candidate on behalf of a major Cambridge, MA biotechnology company. The aim is to elucidate adverse events profiles and repositioning opportunities using Biovista’s proprietary development platform.

By defining the adverse events profile, the design of the clinical trial and choice of specific compounds will be optimized. In addition, repositioning of the candidates will allow alternative indications to be explored in case the clinical end points are not met or the adverse event profile for the original indications is unacceptable.

Financial and other terms of the project were not disclosed.